Phase I, multicenter, open‐label, dose‐escalation study of sonidegib in Asian patients with advanced solid tumors

Sonidegib is a selective inhibitor of Smoothened receptor, which is a key regulator of the Hedgehog signaling pathway. The purpose of this study was to determine the maximum tolerated dose based on dose‐limiting toxicity (DLT) and the recommended dose (RD) of sonidegib in Asian patients with advance...

Descripción completa

Detalles Bibliográficos
Autores principales: Minami, Hironobu, Ando, Yuichi, Ma, Brigette Buig Yue, Hsiang Lee, Jih‐, Momota, Hiroyuki, Fujiwara, Yutaka, Li, Leung, Fukino, Koichi, Ito, Koji, Tajima, Takeshi, Mori, Asuka, Lin, Chia‐Chi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084670/
https://www.ncbi.nlm.nih.gov/pubmed/27467121
http://dx.doi.org/10.1111/cas.13022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084670/
https://www.ncbi.nlm.nih.gov/pubmed/27467121
http://dx.doi.org/10.1111/cas.13022

Ejemplares similares